Ebola and Marburg virus vaccines
AbstractThe filoviruses, Ebola virus (EBOV), and Marburg virus (MARV), are among the most pathogenic viruses known to man and the causative agents of viral hemorrhagic fever outbreaks in Africa with case fatality rates of up to 90%. Nearly 30,000 infections were observed in the latest EBOV epidemic in West Africa; previous outbreaks were much smaller, typically only affecting less than a few hundred people. Compared to other diseases such as AIDS or Malaria with millions of cases annually, filovirus hemorrhagic fever (FHF) is one of the neglected infectious diseases. There are no licensed vaccines or therapeutics available to treat EBOV and MARV infections; therefore, these pathogens can only be handled in maximum containment laboratories and are classified as select agents. Under these limitations, a very few laboratories worldwide conducted basic research and countermeasure development for EBOV and MARV since their respective discoveries in 1967 (MARV) and 1976 (EBOV). In this review, we discuss several vaccine platforms against EBOV and MARV, which have been assessed for their protective efficacy in animal models of FHF. The focus is on the most promising approaches, which were accelerated in clinical development (phase I –III trials) during the EBOV epidemic in West Africa.
The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.
Americans paid a mostly low-key tribute to those who died serving in the U.S. Armed Forces on Monday, with many Memorial Day events canceled due to the coronavirus outbreak that has killed nearly 100,000 people in the United States alone.
Countries where coronavirus infections are declining could still face an "immediate second peak" if they let up too soon on measures to halt the outbreak, the World Health Organization said on Monday.
Recently, the White House unveiled its ambitious plan to develop a coronavirus vaccine before year ’s end. While many immediately questioned the feasibility of this timeline, we worry that not enough attention has gone to a different but equally important concern: Once we have a vaccine that works, who around the world will actually get to use […]Find jobs at Careers by KevinMD.com. Search thousands of physician, PA, NP, and CRNA jobs now. Learn more.
Africa has so far been spared the worst impact of the coronavirus, but the World Health Organization is worried the continent could face a "silent epidemic" if its leaders do not prioritize testing for it, a WHO envoy said on Monday.
Mink with the coronavirus have infected two people in the Netherlands in what are probably the first such cases of transmission during the epidemic, government and health authorities said on Monday.
ConclusionSince our hospital received the first patient with COVID-19 in Singapore, our centre has managed 16 COVID-19 cases to date. There has not been any healthcare worker in our institution who has contracted COVID-19 through patient contact. We have highlighted for discussion some of the policies and processes to prepare a nuclear medicine service for the COVID-19 threat.
Deaths from the COVID-19 epidemic in Italy climbed by 92 on Monday, against 50 the day before, the Civil Protection Agency said, while the daily tally of new cases dropped to just 300 from 531 on Sunday.
A spat is brewing between Germany’s federal government and state governors over plans by some regional leaders to end pandemic-related restrictions despite fresh clusters of cases across the country